Hiroyuki Okuzawa, president and chief operating officer at Daiichi Sankyo, says the company is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the US. The drugmaker is also working with external contract manufacturers to expand production of the so-called antibody drug conjugates (ADCs). He speaks with Shery Ahn on "Bloomberg: The Asia Trade."

Bloomberg videos, provided by MT Newswires